ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors

textabstractAbstract The landscape of treatment options in NET has changed in the last 5 years. Novel targeted drugs have been introduced and approved for distinct types of NET. Furthermore, with the first randomized trial on 177Lu-DOTATATE peptide receptor targeted therapy (PRRT) in midgut NET, not only approval of this treatment is awaited but also its more widespread use. Techniques and choices of radionuclides have changed over time as well as imaging tools. Recognition of well differentiated NET G3 within the group of neuroendocrine neoplasms G3, has widened the spectrum of chemotherapeutic drugs used in this field. Even more it has become important to provide recommendations for daily clinical practice on how to safely use novel drugs, chemotherapeutic agents and PRRT. The updated ENETS consensus guidelines for standard of care in neuroendocrine tumors (NET) provide a tool to accurately assess the diagnosis of NET and provide practical recommendations for the use of surgery, and the different systemic therapeutic options that are available for the management of NET.

[1]  I. Steffen,et al.  Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours , 2012, European Radiology.

[2]  S. Libutti,et al.  Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. , 2011, Surgery.

[3]  C. Boy,et al.  68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.

[4]  P. Cumming,et al.  Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors , 2011, The Journal of Nuclear Medicine.

[5]  F. Lv,et al.  Laparoscopic ultrasound enhances diagnosis and localization of insulinoma in pancreatic head and neck for laparoscopic surgery with satisfactory postsurgical outcomes. , 2011, Ultrasound in medicine & biology.

[6]  V. Ambrosini,et al.  Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT , 2011, The Journal of Nuclear Medicine.

[7]  H. Amthauer,et al.  68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol , 2011, The Journal of Nuclear Medicine.

[8]  Yi Wang,et al.  Diffusion‐weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics , 2011, Journal of magnetic resonance imaging : JMRI.

[9]  J. Buckels,et al.  Preoperative Localisation and Surgical Management of Insulinoma: Single Centre Experience , 2011, Digestive Surgery.

[10]  P. Veit-Haibach,et al.  Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component , 2011, European Radiology.

[11]  A. Bockisch,et al.  The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors , 2010, Annals of surgery.

[12]  T. Baère,et al.  Endocrine pancreatic tumours: which are the most useful MRI sequences? , 2010, European Radiology.

[13]  I. Kayani,et al.  The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy , 2010, Journal of Nuclear Medicine.

[14]  J. Mortensen,et al.  Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET , 2010, Journal of Nuclear Medicine.

[15]  M. Bergström,et al.  In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. , 2010, Nuclear medicine and biology.

[16]  Ka Kit Wong,et al.  Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. , 2010, Academic radiology.

[17]  E. Baudin,et al.  Hepatic Metastases From Neuroendocrine Tumors With a “Thin Slice” Pathological Examination: They are Many More Than You Think … , 2010, Annals of surgery.

[18]  I. Virgolini,et al.  Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[19]  V. Ambrosini,et al.  68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  A. Kjaer,et al.  F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .

[21]  E. D. de Vries,et al.  Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. , 2009, Critical reviews in oncology/hematology.

[22]  David Gross,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers , 2009, Neuroendocrinology.

[23]  M. Falconi,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors , 2009, Neuroendocrinology.

[24]  E. Krenning,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs , 2009, Neuroendocrinology.

[25]  R. Bale,et al.  Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009, Journal of Nuclear Medicine.

[26]  E. Krenning,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide , 2009, Neuroendocrinology.

[27]  Pierre Bedossa,et al.  Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. , 2009, Radiology.

[28]  G. Kaltsas,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations , 2008, Neuroendocrinology.

[29]  J. Walecki,et al.  Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs , 2008, Journal of Nuclear Medicine.

[30]  P. Erba,et al.  Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[31]  A. Groves,et al.  A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors , 2008, Journal of Nuclear Medicine.

[32]  V. Ambrosini,et al.  Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  A. Kjaer,et al.  Quantitative Gene Expression of Somatostatin Receptors and Noradrenaline Transporter Underlying Scintigraphic Results in Patients with Neuroendocrine Tumors , 2008, Neuroendocrinology.

[34]  V. Deshpande,et al.  Improved Contemporary Surgical Management of Insulinomas: A 25-year Experience at the Massachusetts General Hospital , 2008, Annals of surgery.

[35]  F. Zeinali,et al.  Endoscopic ultrasonography (EUS) in the localization of insulinoma , 2007, Endocrine.

[36]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[37]  M. Zahiah,et al.  Intraoperative Ultrasound with Palpation is Still Superior to Intra-arterial Calcium Stimulation Test in Localising Insulinoma , 2007, World Journal of Surgery.

[38]  A. Ignee,et al.  Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography , 2007, Scandinavian journal of gastroenterology.

[39]  J. Saurin,et al.  Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. , 2006, Radiology.

[40]  S. Choi,et al.  LOCALIZATION AND SURGICAL TREATMENT OF THE PANCREATIC INSULINOMAS , 2006, ANZ journal of surgery.

[41]  E. D. de Vries,et al.  Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. , 2006, The Lancet. Oncology.

[42]  Wei Yang,et al.  The role of contrast-enhanced sonography of focal liver lesions before percutaneous biopsy. , 2006, AJR. American journal of roentgenology.

[43]  A. Hubalewska-Dydejczyk,et al.  99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  H. Lochs,et al.  The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. , 2006, Gastrointestinal endoscopy.

[45]  V. Vilgrain,et al.  Endocrine Pancreatic Tumours and Helical CT: Contrast Enhancement Is Correlated with Microvascular Density, Histoprognostic Factors and Survival , 2006, Pancreatology.

[46]  S. Libutti,et al.  A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. , 2005, Surgery.

[47]  Filippo Cademartiri,et al.  Liver haemangiomas undetermined at grey-scale ultrasound: contrast-enhancement patterns with SonoVue and pulse-inversion US , 2005, European Radiology.

[48]  A. Harris,et al.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression , 2004, British Journal of Cancer.

[49]  A. Ferrari,et al.  EUS-guided FNA in the diagnosis of pancreatic neuroendocrine tumors before surgery. , 2004, Gastrointestinal endoscopy.

[50]  A. Ba-Ssalamah,et al.  The importance of preoperative localisation procedures in organic hyperinsulinism — Experience in 67 patients , 2004, Wiener Klinische Wochenschrift.

[51]  R. Wahl,et al.  Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS , 2004, Abdominal Imaging.

[52]  H. Gouya,et al.  CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. , 2003, AJR. American journal of roentgenology.

[53]  M. Kanematsu,et al.  Spectrum of MRI appearances of untreated metastases of the liver. , 2003, AJR. American journal of roentgenology.

[54]  J. Fletcher,et al.  Preoperative detection of pancreatic insulinomas on multiphasic helical CT. , 2003, AJR. American journal of roentgenology.

[55]  J. Norton,et al.  Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025-6. , 2001, Archives of surgery.

[56]  M. Falconi,et al.  Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization , 2001, European Radiology.

[57]  Michelle A. Anderson,et al.  Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas , 2000, American Journal of Gastroenterology.

[58]  T. Ichikawa,et al.  Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. , 2000, Radiology.

[59]  B. Wiedenmann,et al.  Endoscopic Ultrasonography of Neuroendocrine Tumours , 2000, Digestion.

[60]  A. Ferrari,et al.  Role of EUS in the preoperative localization of insulinomas compared with spiral CT. , 2000, Gastrointestinal endoscopy.

[61]  U. Mueller-Lisse,et al.  Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. , 2000, Radiology.

[62]  C. Angelis,et al.  Endosonography in decision making and management of gastrointestinal endocrine tumors. , 1999, European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology.

[63]  J. Doppman,et al.  Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  D. Huglo,et al.  Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. , 1998, Surgery.

[65]  S. Fanti,et al.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours , 1998, European Journal of Nuclear Medicine.

[66]  J. Laissue,et al.  Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. , 1997, The Yale journal of biology and medicine.

[67]  S. Sironi,et al.  Value of abdominal sonography and MR imaging at 0.5 T in preoperative detection of pancreatic insulinoma: a comparison with dynamic CT and angiography , 1997, Abdominal Imaging.

[68]  J. Doppman,et al.  Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. , 1997, Gastroenterology.

[69]  H. Buhr,et al.  Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. , 1996, Gut.

[70]  Y. Chapuis,et al.  Endoscopic Ultrasonography for the Preoperative Localization of Insulinomas , 1996, Pancreas.

[71]  T. Frieling,et al.  Prospective study on the detection of insulinomas by endoscopic ultrasonography. , 1996, Endoscopy.

[72]  P. Ruszniewski,et al.  Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. , 1995, Surgery.

[73]  E. Krenning,et al.  Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. , 1994, European journal of pharmacology.

[74]  B. Wiedenmann,et al.  Localisation of neuroendocrine tumours of the upper gastrointestinal tract. , 1994, Gut.

[75]  J. Laissue,et al.  Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. , 1992, Gastroenterology.

[76]  C. Lightdale,et al.  Localization of pancreatic endocrine tumors by endoscopic ultrasonography. , 1992, The New England journal of medicine.

[77]  W. Lees,et al.  Endoscopic ultrasound for localisation of islet cell tumours. , 1992, Gut.

[78]  E. Goetzl,et al.  Distinct subsets of somatostatin receptors on cultured human lymphocytes. , 1989, The Journal of biological chemistry.

[79]  B Gorman,et al.  Localization of pancreatic insulinoma: comparison of pre- and intraoperative US with CT and angiography. , 1988, Radiology.

[80]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[81]  R. Bale,et al.  Tyr 3 -Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009 .

[82]  C. Nanni,et al.  68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[83]  T. de Baère,et al.  Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  T. de Baère,et al.  MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. , 2003, AJR. American journal of roentgenology.

[85]  J. Laissue,et al.  Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.

[86]  J. Valentin,et al.  Radiation dose to patients from radiopharmaceuticals , 1998 .

[87]  J. Mcnamara,et al.  Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound. , 1998, American journal of surgery.

[88]  J C Reubi,et al.  Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.